AR094987A1 - Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activo - Google Patents
Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activoInfo
- Publication number
- AR094987A1 AR094987A1 ARP140100703A ARP140100703A AR094987A1 AR 094987 A1 AR094987 A1 AR 094987A1 AR P140100703 A ARP140100703 A AR P140100703A AR P140100703 A ARP140100703 A AR P140100703A AR 094987 A1 AR094987 A1 AR 094987A1
- Authority
- AR
- Argentina
- Prior art keywords
- physiologically active
- active polypeptide
- preparation
- conjugate
- high performance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a un procedimiento de preparación de un conjugado engarzando un polipéptido fisiológicamente activo, un engarce de polímero no peptidilo y una región constante de inmunoglobulina mediante un enlace covalente. Más particularmente. la presente se refiere a un procedimiento de preparación eficiente del conjugado de polipéptido fisiológicamente activo, en el que se utiliza una sal en una reacción de acoplamiento para mejorar el problema de bajo rendimiento de la producción durante la preparación del conjugado de polipéptido fisiológicamente activo. Puede producirse el complejo de polipéptido fisiológicamente activo, polímero no peptidilo y una región constante de inmunoglobulina con alta pureza y alto rendimiento mediante el procedimiento descrito de preparación. Debido al procedimiento de preparación del conjugado de polipéptido fisiológicamente activo, pueden reducirse los costos de producción. Por lo tanto, puede utilizarse el procedimiento para desarrollar formulaciones de acción prolongada de polipéptidos fisiológicamente activos, que mejoran la aplicabilidad industrial y el cumplimiento con las reglamentaciones sobre fármacos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130023602 | 2013-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094987A1 true AR094987A1 (es) | 2015-09-09 |
Family
ID=51491612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100703A AR094987A1 (es) | 2013-03-05 | 2014-03-05 | Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activo |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10660940B2 (es) |
| EP (1) | EP2966083B1 (es) |
| JP (1) | JP6374412B2 (es) |
| KR (1) | KR102136336B1 (es) |
| CN (2) | CN110590903A (es) |
| AR (1) | AR094987A1 (es) |
| AU (1) | AU2014226741B2 (es) |
| BR (1) | BR112015021764B1 (es) |
| CA (1) | CA2903365C (es) |
| ES (1) | ES2743612T3 (es) |
| HK (1) | HK1217717A1 (es) |
| IL (1) | IL240869B (es) |
| MX (1) | MX367817B (es) |
| MY (1) | MY186423A (es) |
| NZ (1) | NZ712948A (es) |
| PH (1) | PH12015501952B1 (es) |
| PT (1) | PT2966083T (es) |
| RU (1) | RU2677796C9 (es) |
| SA (1) | SA515360980B1 (es) |
| SG (1) | SG11201506937RA (es) |
| TW (1) | TWI647240B (es) |
| WO (1) | WO2014137161A1 (es) |
| ZA (1) | ZA201507312B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| KR20190038456A (ko) * | 2017-09-29 | 2019-04-08 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
| KR102334315B1 (ko) | 2019-07-18 | 2021-12-06 | 한미약품 주식회사 | 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| AU5943201A (en) * | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| KR101085375B1 (ko) * | 2003-02-26 | 2011-11-21 | 넥타르 테라퓨틱스 | 중합체-인자 ⅷ 부분 콘쥬게이트 |
| EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| CN102065886A (zh) * | 2008-04-14 | 2011-05-18 | 哈洛齐梅公司 | 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用 |
| TWI388570B (zh) * | 2008-07-23 | 2013-03-11 | Hanmi Science Co Ltd | 包含具有三個官能端的非肽醯聚合物的多肽複合物 |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
-
2014
- 2014-03-05 NZ NZ712948A patent/NZ712948A/en unknown
- 2014-03-05 EP EP14760968.9A patent/EP2966083B1/en active Active
- 2014-03-05 JP JP2015561270A patent/JP6374412B2/ja active Active
- 2014-03-05 ES ES14760968T patent/ES2743612T3/es active Active
- 2014-03-05 US US14/772,493 patent/US10660940B2/en active Active
- 2014-03-05 MY MYPI2015002182A patent/MY186423A/en unknown
- 2014-03-05 AU AU2014226741A patent/AU2014226741B2/en active Active
- 2014-03-05 CA CA2903365A patent/CA2903365C/en active Active
- 2014-03-05 KR KR1020140026256A patent/KR102136336B1/ko active IP Right Grant
- 2014-03-05 CN CN201910874160.1A patent/CN110590903A/zh active Pending
- 2014-03-05 PT PT14760968T patent/PT2966083T/pt unknown
- 2014-03-05 BR BR112015021764-8A patent/BR112015021764B1/pt active IP Right Grant
- 2014-03-05 RU RU2015139510A patent/RU2677796C9/ru active
- 2014-03-05 MX MX2015011668A patent/MX367817B/es active IP Right Grant
- 2014-03-05 TW TW103107577A patent/TWI647240B/zh not_active IP Right Cessation
- 2014-03-05 WO PCT/KR2014/001818 patent/WO2014137161A1/ko active Application Filing
- 2014-03-05 AR ARP140100703A patent/AR094987A1/es active IP Right Grant
- 2014-03-05 CN CN201480011914.6A patent/CN105143255B/zh active Active
- 2014-03-05 SG SG11201506937RA patent/SG11201506937RA/en unknown
-
2015
- 2015-08-27 IL IL240869A patent/IL240869B/en active IP Right Grant
- 2015-09-03 PH PH12015501952A patent/PH12015501952B1/en unknown
- 2015-09-03 SA SA515360980A patent/SA515360980B1/ar unknown
- 2015-10-02 ZA ZA2015/07312A patent/ZA201507312B/en unknown
-
2016
- 2016-05-18 HK HK16105703.9A patent/HK1217717A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
| CY1116835T1 (el) | Νεο ευρωπαϊκο στελεχος toy prrsv | |
| AR094987A1 (es) | Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activo | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
| EA201690780A1 (ru) | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство | |
| MX363512B (es) | Proceso de glicoconjugacion. | |
| MX340090B (es) | Analogos de spliceostatina. | |
| CY1117100T1 (el) | Συμπλοκο υδραλογονου της αγομελατινης και μεθοδος παρασκευης του | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
| AR090281A1 (es) | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo | |
| UY33483A (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento. | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| CR20120462A (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| CY1120044T1 (el) | Παρασκευασμα κολονοσκοπησης | |
| CY1117151T1 (el) | Μεθοδος για την παρασκευη διαλυματος λεβοθυροξινης | |
| ZA201409023B (en) | Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein | |
| NZ767670A (en) | Biomolecule conjugates | |
| EA201301321A1 (ru) | Изготовление и использование пероральных фармацевтических композиций на основе митохондриально-адресованных антиоксидантов | |
| EA201200756A1 (ru) | Лиофилизат соединения бороновой кислоты | |
| CR20150160A (es) | Derivados de macrólidos, su preparación y su uso terapéutico | |
| CL2013002534A1 (es) | Metodo de preparacion de un polipeptido antibacterial recombinante; medio de cultivo. | |
| AR089079A1 (es) | Formulacion de anticuerpo anti-cd44 | |
| DOP2013000284A (es) | Derivados de pirazol útiles como inhibidores de aldosterona sintasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |